Skip to content
Sharism- Lifestyle
Author:
Revelation Biosciences, Inc.
Revelation Biosciences, Inc. Announces Financial Results for the Three and Six Months Ended June 30, 2026
August 6, 2026
Independent Market Assessment Results Show $94 Billion Total Addressable Market for Gemini in Stage 2 and Stage 3 Acute Kidney Injury
August 3, 2026
Revelation Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
July 21, 2026
Revelation Biosciences Announces Adoption of Stockholder Rights Plan
July 10, 2026
Revelation Biosciences Expands Acute Kidney Injury Advisory Board
June 1, 2026
Revelation Biosciences, Inc. Releases Corporate Update Letter to Stockholders
May 11, 2026
Revelation Biosciences, Inc. Announces Financial Results For the Three Months Ended March 31, 2026
May 8, 2026
Revelation Biosciences Announces Formation of Acute Kidney Injury Advisory Board
April 6, 2026